Ulcerative Colitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Ulcerative Colitis - Pipeline Review, H2 2018’, provides an overview of the Ulcerative Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis

- The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects

- The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

AbbVie Inc

AbGenomics International Inc

Abivax SA

Adello Biologics LLC

Akebia Therapeutics Inc

Allergan Plc

Alpha Cancer Technologies Inc

Alvotech Iceland

Am-Pharma ...

4D Pharma PLC

AbbVie Inc

AbGenomics International Inc

Abivax SA

Adello Biologics LLC

Akebia Therapeutics Inc

Allergan Plc

Alpha Cancer Technologies Inc

Alvotech Iceland

Am-Pharma BV

Amgen Inc

Antibe Therapeutics Inc

Aptevo Therapeutics Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Atlantic Bio Sci LLC

Atlantic Healthcare Plc

Avexegen Therapeutics Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Cellix Bio Pvt Ltd

Celltrion Inc

ChemoCentryx Inc

ChironWells GmbH

Chong Kun Dang Pharmaceutical Corp

Coherus BioSciences Inc

Cosmo Pharmaceuticals NV

Dr. August Wolff GmbH & Co KG Arzneimittel

EA Pharma Co Ltd

Eli Lilly and Co

Enceladus Pharmaceuticals BV

enGene Inc

Enterome Bioscience SA

Evelo Biosciences Inc

Ferring International Center SA

Fresenius SE & Co KGaA

Galapagos NV

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Gossamer Bio Inc

IB Pharmaceuticals Inc

iCo Therapeutics Inc

Inception Sciences Inc

Incyte Corp

InDex Pharmaceuticals Holding AB

InSight Biopharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Istesso Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kaken Pharmaceutical Co Ltd

Keystone Biologics Inc

Kyowa Hakko Kirin Co Ltd

LG Chem Ltd

LIPID THERAPEUTICS GmbH

Lycera Corp

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Nash Pharmaceuticals Inc

Nextbiotix SAS

Nichi-Iko Pharmaceutical Co Ltd

Nyrada Inc

Ogeda SA

OSE Immunotherapeutics

Palatin Technologies Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Pharmaxis Ltd

Protab Ltd

Protagonist Therapeutics Inc

Protalix BioTherapeutics Inc

Qu Biologics Inc

Re-Pharm Ltd

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Sandoz International GmbH

Sareum Holdings Plc

Seres Therapeutics Inc

Shire Plc

sterna biologicals Gmbh & Co KG

Sublimity Therapeutics Ltd

Swedish Orphan Biovitrum AB

Synedgen Inc

Synergy Pharmaceuticals Inc

Synlogic Inc

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tillotts Pharma AG

TopiVert Ltd

Ventria Bioscience

Vivelix Pharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Ulcerative Colitis - Overview 8

Ulcerative Colitis - Therapeutics Development 9

Ulcerative Colitis - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 7

Ulcerative Colitis - Overview 8

Ulcerative Colitis - Therapeutics Development 9

Ulcerative Colitis - Therapeutics Assessment 31

Ulcerative Colitis - Companies Involved in Therapeutics Development 45

Ulcerative Colitis - Drug Profiles 88

Ulcerative Colitis - Dormant Projects 500

Ulcerative Colitis - Discontinued Products 508

Ulcerative Colitis - Product Development Milestones 510

Appendix 523

List of Tables

List of Tables

Number of Products under Development for Ulcerative Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Ulcerative Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ulcerative Colitis - Pipeline by 4D Pharma PLC, H2 2018

Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2018

Ulcerative Colitis - Pipeline by AbGenomics International Inc, H2 2018

Ulcerative Colitis - Pipeline by Abivax SA, H2 2018

Ulcerative Colitis - Pipeline by Adello Biologics LLC, H2 2018

Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Allergan Plc, H2 2018

Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2018

Ulcerative Colitis - Pipeline by Alvotech Iceland, H2 2018

Ulcerative Colitis - Pipeline by Am-Pharma BV, H2 2018

Ulcerative Colitis - Pipeline by Amgen Inc, H2 2018

Ulcerative Colitis - Pipeline by Antibe Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H2 2018

Ulcerative Colitis - Pipeline by Artelo Biosciences Inc, H2 2018

Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H2 2018

Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2018

Ulcerative Colitis - Pipeline by Avexegen Therapeutics Inc, H2 2018

Ulcerative Colitis - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Co, H2 2018

Ulcerative Colitis - Pipeline by Celgene Corp, H2 2018

Ulcerative Colitis - Pipeline by Cellix Bio Pvt Ltd, H2 2018

Ulcerative Colitis - Pipeline by Celltrion Inc, H2 2018

Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H2 2018

Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2018

Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Ulcerative Colitis - Pipeline by Coherus BioSciences Inc, H2 2018

Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Ulcerative Colitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2018

Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H2 2018

Ulcerative Colitis - Pipeline by Eli Lilly and Co, H2 2018

Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2018

Ulcerative Colitis - Pipeline by enGene Inc, H2 2018

Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2018

Ulcerative Colitis - Pipeline by Evelo Biosciences Inc, H2 2018

Ulcerative Colitis - Pipeline by Ferring International Center SA, H2 2018

Ulcerative Colitis - Pipeline by Fresenius SE & Co KGaA, H2 2018

Ulcerative Colitis - Pipeline by Galapagos NV, H2 2018

Ulcerative Colitis - Pipeline by Genentech Inc, H2 2018

List of Figures

List of Figures

Number of Products under Development for Ulcerative Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Ulcerative Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports